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Abstract
© 2015 Nikonova, Deneka, Eckman, Kopp, Hensley, Egleston and Golemis. Aurora-A kinase
(AURKA) overexpression in numerous tumors induces aneuploidy, in part because of cytokinetic
defects. Alisertib and other small-molecule inhibitors targeting AURKA are effective in some
patients as monotherapies or combination therapies. Epidermal growth factor receptor (EGFR)
pro-proliferative signaling activity  is  commonly  elevated in  cancer,  and the EGFR inhibitor
erlotinib  is  commonly  used  as  a  standard  of  care  agent  for  cancer.  An  erlotinib/alisertib
combination therapy is currently under assessment in clinical trials, following pre-clinical studies
that indicated synergy of these drugs in cancer. We were interested in further exploring the
activity  of  this  drug  combination.  Beyond  well-established  functions  for  AURKA  in  mitotic
progression,  additional  non-mitotic  AURKA functions  include  control  of  ciliary  stability  and
calcium signaling. Interestingly, alisertib exacerbates the disease phenotype in mouse models
for  autosomal-dominant  polycystic  kidney disease (ADPKD),  a  common inherited syndrome
induced by aberrant signaling from PKD1 and PKD2, cilia-localized proteins that have calcium
channel activity. EGFR is also more active in ADPKD, making erlotinib also of potential interest in
this disease setting. In this study, we have explored the interaction of alisertib and erlotinib in
an  ADPKD model.  These  experiments  indicated  erlotinib-restrained  cystogenesis,  opposing
alisertib action. Erlotinib also interacted with alisertib to regulate proliferative signaling proteins,
albeit in a complicated manner. Results suggest a nuanced role of AURKA signaling in different
pathogenic conditions and inform the clinical use of AURKA inhibitors in cancer patients with
comorbidities.
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